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Summary The surface glycoprotein CD44 is widely distributed in different tissues. In contrast to healthy
tissue, tumour samples show a more complex pattern of CD44 expression, indicating a loss of splice control.
Beside cell-surface expression, the measurement of soluble CD44 in serum of cancer patients could be useful in
early diagnosis and assessment of disease status. We evaluated the surface expression of CD44 isoforms in 22
ovarian cancer patients by means of immunohistochemistry. Additionally, we investigated 134 serological
samples of these patients for the occurrence of CD44 isoform expression. For CD44standard, CD44v5 and
CF44v6 mean serum levels in patients with clinically detectable or non-detectable ovarian cancer were
422.4 ± 143.8 ng ml- and 547.4 ± 148.2 ng ml ', 12.3 ± 7.9 ng ml-' and 21.9 ± 12.2 ng ml-' and 105.5
+ 37.9 ng ml-' and 144.9 ± 50.9 ng ml-' respectively (P-values not significant). CD44 surface proteins con-
taining epitopes encoded by splice variants CD44v5, CD44v6 and CD44v7-8 were immunohistochemically
detected in 9% (n = 2), 13% (n = 3) and 4% (n = 1) of the 22 tumour samples respectively. In the present
study we showed that in ovarian cancer CD44 isoforms CD44v5 and CD44v6 are expressed in very low
amounts by the tumours. In accordance with this, we found that the presence of tumour is not associated with
higher serum levels of CD44standard, CD44v5 and CD44v6 in preoperative serum samples in ovarian cancer
patients.
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Ovarian cancer is diagnosed at advanced stages in approx-
imately 75% of patients. The prognosis in ovarian cancer
remains poor, and there is a need to identify patients less
likely to respond to treatment or patients who suffer from
low-stage disease and have a worse prognosis. Early detec-
tion of ovarian cancer or of recurrent disease after primary
therapy is very important in ovarian cancer patients. Serum
tumour markers, which have been shown to be useful in early
detection of primary tumours, recurrences, evaluation of pro-
gnosis and monitoring of therapy, have become an integral
part of follow-up schemes in the management of ovarian
cancer patients (Tarin and Matsumura, 1993; Dall et al.,
1994; Gold and Osband, 1994).
The surface glycoprotein CD44 is widely distributed in
different tissues (Flanagan et al., 1989). CD44 cell-surface
adhesion molecules have been shown to mediate cell-cell and
cell-matrix interactions (Screaton et al., 1992), allowing cir-
culating lymphocytes to migrate into lymphatic tissue (Jal-
kanen et al., 1986; Salles et al., 1993) and to control lym-
phocyte binding to peripheral lymph nodes, mucosal and
synovial endothelial cells (Jalkanen et al., 1987a). The CD44
family of transmembrane receptor molecules is derived from
a single gene located on chromosome 11 (Koopman et al.,
1993). By the mechanism of 'messenger RNA alternative
splicing' numerous isoforms of the CD44 glycoprotein are
produced (Smith et al., 1989; Matsumura and Tarin, 1992;
Screaton et al., 1992). Cell-surface proteins encoded by splice
variants of CD44 differ from the CD44 standard isoform by
additional amino acids in the extracellular region of the
protein (Screaton et al., 1992). CD44 isoforms encoded by
splice variants occur on the surface of different normal cells
(Mackay et al. 1994). Tumour samples show a more com-
plex pattern of CD44 expression, indicating a loss of splice
control in malignantly transformed cells (Heider et al., 1993).
Rudy et al. (1993) could show that the expression of variants
of the CD44 surface glycoprotein confers metastatic behav-
iour to a non-metastatic cell line in a rat carcinoma model
(Gunthert et al., 1991). In colorectal cancer, breast and cer-
vical cancer as well as in gastrointestinal lymphoma and
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gastric cancer a correlation between the overexpression of
specific isoforms of CD44 and poor prognosis was reported
(Joensuu et al., 1993a, b; Mayer et al., 1993; Wielenga et al.,
1993; Kainz et al., 1995a).
It was speculated that the overexpression of specific CD44
isoforms, mainly CD44 splice variants v5, v6 and v7-8,
could raise the metastatic potential of a tumour by
facilitating the expansion of malignant cells into the draining
lymph nodes (Salles et al., 1993).
Antibodies raised against different soluble CD44 molecules
allow the detection of CD44 isoforms in serum samples. The
measurement of soluble CD44 molecules in body fluids could
be useful in early diagnosis of cancer, assessment of disease
status and evaluation of metastatic potential and prognosis.
In a recent study we investigated the serum levels of pro-
teins encoded by CD44 splice variants in cervical cancer
patients and found significantly elevated levels of CD44v6
when tumour was present (Kainz et al., 1995b). AG Zeimet
et al. (personal communication) describe high serum levels of
the CD44standard molecule in ovarian cancer patients when
tumour is present.
This prompted us to evaluate the levels of CD44 glycop-
roteins encoded by CD44standard and CD44 splice variants
vS and v6 in serum samples of women suffering from ovarian
cancer. Furthermore, we evaluated the immunohistochemical
expression of epitopes encoded by CD44 splice variants v5,
v6 and v7-8 in tumour specimens from the same sample of
patients.
Patients and methods
This study includes 134 clinical and serological examinations
of 22 patients suffering from ovarian cancer FIGO stages
I-IV. All patients were treated by hysterectomy, lymph node
sampling and omentectomy followed by a platinum-cont-
aining chemotherapy. All patients underwent a close follow-
up programme consisting of regular visits at 3 month inter-
vals, including vaginorectal palpation and ultrasound exam-
ination of the lower abdominal tract. Computertomography
of the pelvis was performed every 6 months. Serum samples
were taken before therapy and during a follow-up period of
at least 12 months and up to 36 months and were stored at
-20°C.The patients were selected randomly. One preoperative
serum sample and a minimum of four post-operative serum
samples were available from every patient. In cases of
tumour relapse at least five post-operative serum samples
before the time of clinical evidence of relapse were available.
Serum assay
Serum levels of soluble CD44 isoforms CD44standard,
CD44v5 and CD44v6 were measured using the sCD44stand-
ard (st) enzyme-linked immunosorbent assay (ELISA),
sCD44var (vS) ELISA and sCD44var (v6) ELISA (Bender
Med Systems, Bender, Vienna, Austria) respectively. All tests
were run in duplicate according to manufacturer's instruc-
tions and without knowledge of the clinical outcome. A panel
of 22 sera from healthy blood donors were tested for serum
levels of CD44standard, CD44v5 and CD44v6.
To define the specificity of these ELISAs several struc-
turally related and non-related polypeptides were tested for
cross-reactivity. There is no detectable cross-reactivity with
CD44 polypeptides lacking the protein sequence encoded by
the corresponding exons. The limit of detection of soluble
CD44 molecules (sensitivity) by antibodies used in these
experiments was determined to be between 0.07 and
0.22 ng ml-'. Intra-assay and inter-assay reproducibility has
been calculated to be between 3% and 5.8%.
Immunohistochemistry
A total of 22 routinely formalin-fixed and paraffin-embedded
surgery samples were used to evaluate the expression of
epitopes encoded by CD44 splice variants CD44vS, CD44v6
and CD44v7-8. The paraffin sections were soaked in xylene
to remove paraffin and rehydrated in a graded alcohol series
(100-70%). To recover antigenicity we used the 'Antigen
Retrieval System' (Bio Genex, San Ramon, CA, USA) twice
for 20 min in a microwave at 600 W power (HM 146, Elektra
Bregenz, Schwaz, Austria) and then the sections were washed
in 10 mM phosphate-buffered saline (PBS) (pH 7.6) Three
different primary antibodies to different epitopes encoded by
CD44 splice variants were used. The first was a monoclonal
antibody specific for the epitope encoded by exon vS of
human variant CD44 (CD44v5, clone VFF-8, Bender), the
second monoclonal antibody was specific for the epitope
encoded by exon v6 of human variant CD44 (CD44v6, clone
VFF-7, Bender) and the third monoclonal antibody was
specific for the epitope encoded by exons v7-8 of human
variant CD44 (CD44v7-8, clone VFF-17, Bender). The
primary antibody was diluted in serum/PBS and the sections
were incubated for 60 min and then incubated for 30 min
with biotinylated anti-mouse and anti-rabbit link antibody
(Dako LSAB 2 Kit, Dako, Carpinteria, CA, USA). After
rinsing in PBS the sections were coated with streptavidin
conjugated to alkaline phosphatase for 10 min. The sections
were then rinsed in PBS, incubated with fast red chromogen
(naphtol phosphate substrate in Tris buffer, fast red
chromogen tablets 5 mg, Bio Genex, San Ramon, CA, USA)
and then washed with distilled water. The sections were
finally counterstained with haematoxylin and mounted. We
interpreted strong and/or widespread staining as positive,
weak and focal staining as negative.
Positive control The positive control slide was prepared
from epidermal tissue known to contain the antigen. In the
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positive control tissue all monoclonal antibodies stained
similarly.
Negative control The negative control slide was prepared
from the same tissue block as the specimen. Instead of the
primary antibody we used a normal, non-immune serum
supernatant from the same source as the primary antibody.
Statistics
All results are expressed as mean ± standard error of the
mean. Depending on the type and distribution of the data
group, comparisons were achieved by analysis of variance
(ANOVA) procedures or by Wilcoxon two-sample test. The
significance level assumed was P = 0.05.
Results
Mean age of the patients at the time of diagnosis was
57.6 ± 16.7 (range 26-89) years. Ovarian cancer stages 1, II,
III and IV were present in three, five, ten and four cases.
Serous, mucinous cystadenocarcinoma, undifferentiated car-
cinoma and adenocarcinoma were present in nine, eight,
three and two cases respectively. Our material included 76
and 58 serum samples of women with and without evidence
of disease respectively.
The detected mean levels of healthy donors were 443
+125ngml-', 35± 13ngml-' and 170±54ngml-' for
CD44standard, CD44v5 and CD44v6 respectively. For
CD44standard mean serum levels in patients with clinically
detectable or clinically non-detectable ovarian cancer were
422.4 ± 143.8 ng ml-' and 547.4 ± 148.2 ng ml-' respectively
(P-value not significant). For CD44vS we measured a mean
serum concentration in serum samples with clinically detec-
table tumour or not of 12.3 ± 7.9 ng ml-' and 21.9 ± 12.2 ng
ml-' respectively (P-value not significant). Proteins encoded
by the splice variant CD44v6 showed a mean concentration
of 105.5 ± 37.9 ngml-' when tumour was present and a
mean concentration of 144.9 ± 50.9 ng ml-' in cases of com-
plete remission (P-value not significant).
Serum levels of CD44 isoforms CD44standard, CD44v5
CD44v6 and CD44v7, grouped by the following clinical
features: before therapy, complete remission, partial remiss-
ion, steady disease and progression, are shown in Table I.
We found no significant differences between mean serum
levels when pre-treatment samples were grouped by stage,
histological type of tumour and lymph node involvement.
Eight patients developed recurrent disease after complete
remission. No increase of serum levels of CD44st, CD44v5
and CD44v6 could be observed before clinical evidence of
relapse.
Immunohistochemistry
CD44 surface proteins containing epitopes encoded by splice
variants CD44v5, CD44v6 and CD44v7-8 were detected by
means of immunohistochemistry in two, three and one case
of the 22 tumour samples respectively. We found homo-
geneous staining in tumours that were considered positive for
CD44 expression.
We found no correlation between expression of any of the
splice variants and histological type, stage of the tumour or
age of the patient.
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Table I Mean serum levels of CD44standard, CD44v5, CD44v6 and CD44v7 grouped by clinical status expressed as mean ± s.d.
Before therapy Complete remission Partial remission Steady disease Progression
CD44standard (ng ml-') 468.2 ± 137.6 547.4 ± 148.2 359.1 ± 106.2 371.3 ± 132.9 548.8 ± 142.1
CD44v5 (ng ml-') 14.6 ± 12.2 22.0 ± 12.2 12.3 ± 4.0 12.6 ± 5.8 9.5 ± 9.5
CD44v6 (ng ml ') 111.2 ± 46.8 144.9 ± 50.9 110.1 ± 32.0 99.9 ± 27.3 93.7 ± 46.5
CD44v7 (ng ml ') 2.5 ± 3.2 1.6 ± 3.1 2.3 ± 3.7 0.2 ± 0.6 0.3 ± 0.7
Mean serum levels of CD44standard, CD44v5, CD44v6 and CD44v7 grouped by clinical status expressed as mean ± s.d.CD 44 splice variants in ovarian cancer
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Discussion
In a previous study we were able to show that in cervical
cancer patients' elevated CD44v6 serum levels were
significantly correlated with clinical evidence of disease
(Kainz et al., 1995b). CD44 isoforms CD44v5 and
CD44v7-8 were strongly expressed by the tumour cells in
cervical cancer patients. The expression of the CD44 isoform
CD44v6 on tumour cells has been reported to be an indepen-
dent prognostic factor in surgically treated cervical cancer
patients (Kainz et al., 1995c). Although the two above-
mentioned studies examined different patient collectives, the
available data lead to the conclusion that the expression of
CD44v6 on tumour cells is reflected in its serum level.
In the present study we show that in this ovarian cancer
collective the immunohistochemically detected expression rate
of the CD44 isoforms CD44v5 and CD44v6 is very low.
Consequently. serum levels of CD44v5 and CD44v6 in
preoperative samples are not elevated compared with healthy
controls.
Aberrant expression of glycoproteins encoded by CD44
splice variants has been detected by means of immunohisto-
chemistry in human paraffin-embedded tumour samples
(Heider et al., 1993; Tanabe et al., 1993). The expression of
specific CD44 isoforms has been shown to be associated with
metastasis and to be of prognostic relevance in human malig-
nancies such as colorectal cancer, breast and cervical cancer,
gastrointestinal lymphoma and gastric cancer (Joensuu et al.,
1993a; Kainz et al., 1995a; Mayer et al., 1993; Wielenga et
al., 1993).
Our data show that in ovarian cancer serum levels of the
CD44 isoforms CD44v5 and CD44v6 do not reflect the
tumour burden. Confirming that finding, we were able to
show, by means of immunohistochemistry, that epitopes
encoded by CD44 splice variants CD44v5, CD44v6 and
CD44v7-8 are detectable in very low amounts in paraffin-
embedded tissue samples of ovarian cancer patients. No corr-
elation with any clinical or histological parameter was found.
When grouped by clinical status the highest serum levels of
the CD44standard isoform were found in cases of tumour
progression and in cases of complete remission. This is sur-
prising since pretherapeutic serum levels of CD44standard
are not significantly elevated and thus serum levels of
CD44standard does not seem to correlate with the presence
of tumour.
All patients in our collective underwent a post-operative
chemotherapy with six cycles of carboplatin (400 mgm-2)
and cyclophosphamide (600 mg m 2) in a 4 week interval. In
the cases of tumour relapse or progression second-line
chemotherapy with paclitaxel (17 mg m-2) was applied after
a 3 week interval. In order to stimulate peripheral blood
progenitor cells patients were given granulocyte-macrophage
colony-stimulating factor (GM-CSF; 5jig kg-') (de Vries et
al., 1991).
The CD44standard isoform is distributed on haemato-
poietic cells, including all subsets of leucocytes, monocytes
and erythrocytes and on different non-haematopoietic cells
(Jalkanen et al., 1987b; Flanagan et al., 1989; Underhill,
1992). High-dose chemotherapy with the support of peri-
pheral blood progenitor cells (PBPCs) is increasingly used in
the treatment of solid tumours. Inducing PBPC proliferation
by colony-stimulating factors results in up-regulation of
CD34 expression. These cells do also express the CD44-
standard isoform in almost 95% (Mohle et al., 1993; Dicke et
al., 1994).
An increase of haematopoietic cells expressing the CD44-
standard isoform could be responsible for the elevated
CD44st serum levels.
We conclude that CD44 isoforms CD44standard, CD44v6
and CD44v7-8 are expressed at a very low level in malignant
ovarian tumours. Serum levels of soluble CD44 isoforms do
not reflect the tumour burden. Serum CD44standard showed
higher levels when high haematopoietic activity was present.
Therefore we hypothesise that the serum CD44standard pro-
duction in haematopoietic cells overrules the production of
ovarian tumour cells. The serum level of CD44standard
mostly reflects the haematopoietic activity in these patients.
To clarify this matter we are currently examining the
influence of growth factors used in chemotherapy regimens
on the expression of CD44 isoforms.
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